一名卵巢癌患者腹腔感染治疗期间出现耐亚胺培南铜绿假单胞菌。
Emergence of imipenem-resistant Pseudomonas aeruginosa during treatment of intra-abdominal infection in a patient with ovarian carcinoma.
作者信息
Sze E H, Osborne N G, Adelson M D, Granato P
出版信息
J Natl Med Assoc. 1988 Oct;80(10):1133-5.
Abstract
A 59-year-old woman was admitted to the hospital with ovarian carcinoma. After cytoreductive surgery, the patient developed intra-abdominal sepsis. After 17 days of intravenous imipenem, the patient's sputum culture grew imipenem-resistant Pseudomonas aeruginosa. On the 21st day of treatment with imipenem, her peritoneal culture also grew imipenem-resistant Pseudomonas aeruginosa.
摘要
一名59岁女性因卵巢癌入院。细胞减灭术后，该患者发生腹腔内感染。静脉输注亚胺培南17天后，患者痰培养出耐亚胺培南的铜绿假单胞菌。在使用亚胺培南治疗的第21天，其腹膜培养物也培养出耐亚胺培南的铜绿假单胞菌。
相似文献
1
Emergence of imipenem-resistant Pseudomonas aeruginosa during treatment of intra-abdominal infection in a patient with ovarian carcinoma.
J Natl Med Assoc. 1988 Oct;80(10):1133-5.
2
Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes.
Infect Control Hosp Epidemiol. 2006 Sep;27(9):893-900. doi: 10.1086/507274. Epub 2006 Aug 21.
3
The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
Infect Control Hosp Epidemiol. 2009 May;30(5):487-90. doi: 10.1086/596781.
4
Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections.
J Infect. 2009 Apr;58(4):285-90. doi: 10.1016/j.jinf.2009.02.010. Epub 2009 Mar 17.
5
Clinical surveillance of surgical imipenem-resistant Pseudomonas aeruginosa infection in a Japanese hospital.
J Hosp Infect. 2004 Feb;56(2):111-8. doi: 10.1016/j.jhin.2003.10.020.
6
Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns.
Clin Infect Dis. 1997 Nov;25(5):1094-8. doi: 10.1086/516092.
7
Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
Chemioterapia. 1985 Feb;4(1):95-101.
8
[Development of resistance in imipenem therapy in Pseudomonas aeruginosa].
Immun Infekt. 1986 Nov;14(6):224-6.
9
Risk factors for recovery of imipenem- or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil.
Infect Control Hosp Epidemiol. 2006 Sep;27(9):901-6. doi: 10.1086/507288. Epub 2006 Aug 21.
10
Imipenem-resistant Ps. aeruginosa bacteraemia in cancer patients: risk factors, clinical features and outcome.
Bratisl Lek Listy. 1996 Nov;97(11):647-51.
本文引用的文献
1
Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia.
Antimicrob Agents Chemother. 1982 Oct;22(4):564-70. doi: 10.1128/AAC.22.4.564.
2
In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin.
Antimicrob Agents Chemother. 1982 Nov;22(5):906-8. doi: 10.1128/AAC.22.5.906.
3
Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant.
Antimicrob Agents Chemother. 1982 Feb;21(2):299-309. doi: 10.1128/AAC.21.2.299.
4
Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections.
Antimicrob Agents Chemother. 1984 Nov;26(5):673-7. doi: 10.1128/AAC.26.5.673.
5
Resistance of Pseudomonas aeruginosa mutants with altered control of chromosomal beta-lactamase to piperacillin, ceftazidime, and cefsulodin.
Antimicrob Agents Chemother. 1984 Mar;25(3):382-4. doi: 10.1128/AAC.25.3.382.
6
Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group.
Lancet. 1984 Apr 21;1(8382):868-71.
7
Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis.
J Antimicrob Chemother. 1985 Nov;16(5):629-35. doi: 10.1093/jac/16.5.629.
8
Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience.
Rev Infect Dis. 1985 Jul-Aug;7 Suppl 3:S513-7. doi: 10.1093/clinids/7.supplement_3.s513.
9
Mutation of Pseudomonas aeruginosa to piperacillin resistance mediated by beta-lactamase production.
J Antimicrob Chemother. 1985 Jun;15(6):665-70. doi: 10.1093/jac/15.6.665.
10
Empirical use of imipenem as the sole antibiotic in the treatment of serious infections.
J Antimicrob Chemother. 1985 Oct;16(4):499-507. doi: 10.1093/jac/16.4.499.
Zotero 插件